BioVendor - Laboratorni medicina a.s.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioVendor - Laboratorni medicina a.s. - overview
Established
1992
Location
Brno, -, Czech Republic
Primary Industry
Biotechnology
About
BioVendor - Laboratorní medicína a. s. , located in the Czech Republic, specializes in the development and manufacturing of laboratory diagnostic products, including immunoassays and proteins, enhancing medical testing accuracy. Founded in 1992 in Brno, Czech Republic, BioVendor - Laboratorní medicína a.
s. focuses on diagnostic solutions. The company has successfully completed a total of 3 deals, with the most recent deal occurring on March 10, 2025. The current CEOs are Martin Zeppetzauer and Michal Kostka.
BioVendor Research and Diagnostic Products specializes in developing and manufacturing immunoassays, recombinant proteins, antibodies, and endotoxin-removal products. Their offerings focus on high-purity reagents that enhance the accuracy and reliability of laboratory research. Notable products include the Corticosteroid-Binding Globulin Human ELISA and Human Uromodulin ELISA, which cater to various diagnostic needs. The company's products are utilized by clinical laboratories and healthcare providers primarily in Europe and North America.
In 2023, BioVendor achieved a revenue of USD 29. 28 mn and an EBITDA of USD 2. 99 mn. The company generates its revenue through direct sales of specialized diagnostic products and services to laboratories and healthcare institutions via a B2B model.
In March 2025, ARCHIMED acquired a majority stake in BioVendor - Laboratorní medicína a. s. , with the aim of supporting the company's growth. Future initiatives include the development of new diagnostic products and expansion into new geographic markets.
Specific plans for market expansion will be detailed closer to the planned product releases.
Current Investors
Archimed
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.biovendor.group/
Total Amount Raised
Subscriber access only
BioVendor - Laboratorni medicina a.s. - timeline of key events
BioVendor - Laboratorni medicina a.s. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 390,421,000 | 421,148,000 | 431,221,000 | 719,074,000 | 600,837,000 | 499,895,000 | 529,748,000 | 1,478,293,000 | 1,511,064,000 | 1,962,229,000 | 2,446,014,000 | - | - | - |
| % Revenue Growth (YoY) | - | 7.9% | 2.4% | 66.8% | (16.4%) | (16.8%) | 6.0% | 179.1% | 2.2% | 29.9% | 24.7% | - | - | - |
| EBITDA (USD) | 86,497,000 | 96,773,000 | 91,476,000 | 164,630,000 | 111,551,000 | 90,674,000 | 82,963,000 | 296,451,000 | 251,897,000 | 489,826,000 | 640,081,000 | - | - | - |
| Operating Income (USD) | 42,610,000 | 50,217,000 | 51,065,000 | 117,667,000 | 65,776,000 | 42,250,000 | 31,302,000 | 179,594,000 | 113,751,000 | 344,190,000 | 483,967,000 | - | - | - |
| Operating Margin | 10.9% | 11.9% | 11.8% | 16.4% | 10.9% | 8.5% | 5.9% | 12.1% | 7.5% | 17.5% | 19.8% | - | - | - |
| % EBITDA Margin | 22.2% | 23.0% | 21.2% | 22.9% | 18.6% | 18.1% | 15.7% | 20.1% | 16.7% | 25.0% | 26.2% | - | - | - |
| NET Income (USD) | 26,983,000 | 31,284,000 | 38,259,000 | 67,550,000 | 44,293,000 | 50,052,000 | 25,799,000 | 87,101,000 | 174,417,000 | 260,246,000 | 381,233,000 | - | - | - |
| % Net Margin | 6.9% | 7.4% | 8.9% | 9.4% | 7.4% | 10.0% | 4.9% | 5.9% | 11.5% | 13.3% | 15.6% | - | - | - |
BioVendor - Laboratorni medicina a.s. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | BioVendor - Laboratorni medicina a.s. | - | ||||||||
| Trade Sale | Completed | Immunolab GmbH | - | ||||||||
| Unspecified Exit | Completed | BioVendor - Laboratorni medicina a.s. | - | ||||||||
| Add-on | Completed | Immunolab GmbH | - | ||||||||
| Growth | Completed | BioVendor - Laboratorni medicina a.s. | - |
Displaying 1 - 5 of 5
BioVendor - Laboratorni medicina a.s. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.